Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.
Published January 27, 2016 · Recall initiated: November 4, 2015
Summary
FDA records drug Class II recall D-0581-2016, published January 27, 2016 and initiated November 4, 2015. Recalling firm: Pine Pharmaceuticals, LLC; Status: Terminated; Reported quantity: N/A; Lot: Lot #: 1956@2, exp. 2/2/2016; 1954@1, exp. 2/2/2016; 1958@3, exp. 2/2/2016; 1943@2, exp. 2/1/2016; 1942@1, exp. 2/1/2016; 1944@3, exp. 2/1/2016; 1938@1, exp. 1/31/2016; 1939@2, exp. 1/31/2016; 1931@1, exp. 1/28/2016; 1932@2, exp. 1/28/2016; 1935@3, exp. 1/28/2016; 1925@1, exp. 1/27/2016; 1927@2, exp. 1/27/2016; 1928@3, exp. 1/27/2016; 1913@3, exp. 1/26/2016; 1917@4, exp. 1/26/2016; 1911@1, exp. 1/26/2016; 1921@6, exp. 1/26/2016; 1906@3, exp. 1/25/2016; 1903@1, exp. 1/25/2016; 1904@2, exp. 1/25/2016; 1899@3, exp. 1/24/2016; 1896@2, exp. 1/24/2016; 1895@1, exp. 1/24/2016; 1886@2, exp. 1/21/2016; 1893@5, exp. 1/21/2016; 1890@4, exp. 1/21/2016; 1885@1, exp. 1/21/2016; 1888@3, exp. 1/21/2016; 1879@5, exp. 1/20/2016; 1872@1, exp. 1/20/2016; 1875@3, exp. 1/20/2016; 1873@2, exp. 1/20/2016; 1867@5, exp. 1/19/2016; 1870@6, exp. 1/19/2016; 1866@4, exp. 1/19/2016; 1854@4, exp. 1/18/2016; 1853@5, exp. 1/18/2016; 1855@6, exp. 1/18/2016; 1839@3, exp. 1/17/2016; 1836@1, exp. 1/17/2016; 1831@2, exp. 1/14/2016; 1813@2, exp. 1/14/2016; 1830@1, exp. 1/14/2016; 1825@1, exp. 1/13/2016; 1818@4, exp. 1/13/2016; 1827@2, exp. 1/13/2016; 1816@3, exp. 1/12/2016; 1812@1, exp. 1/13/2016; 1804@4, exp. 12/31/2015; 1799@6, exp. 1/10/2016; 1797@5, exp. 1/10/2016; 1789@3, exp. 1/7/2016; 1635@5, exp. 12/17/2015; 1490@1, exp. 11/25/2015; 1790@4, exp. 1/7/2016; 1633@4, exp. 12/17/2015; 1492@2, exp. 11/25/2015; 1786@1, exp. 1/7/2016; 1628@2, exp. 12/17/2015; 1497@5, exp. 11/25/2015; 1788@2, exp. 1/7/2016; 1629@3, exp. 12/17/2015; 1486@7, exp. 11/24/2015; 1764@1, exp. 1/6/2016; 1617@1, exp. 12/16/2015; 1476@3, exp. 11/24/2015; 1768@3, exp. 1/6/2016; 1623@4, exp. 12/16/2015; 1474@1, exp. 11/24/2015; 1769@4, exp. 1/6/2016; 1620@3, exp. 12/16/2015; 1466@2, exp. 11/23/2015; 1757@2, exp. 1/5/2016; 1625@5, exp. 12/16/2015; 1473@5, exp. 11/23/2015; 1756@1, exp. 1/5/2016; 1618@2, exp. 12/16/2015; 1465@1, exp. 11/23/2015; 1762@4, exp. 1/5/2016; 1608@2, exp. 12/15/2015; 1460@2, exp. 11/22/2015; 1749@3, exp. 1/4/2016; 1610@3, exp. 12/15/2015; 1458@1, exp. 11/22/2015; 1746@1, exp. 1/4/2016; 1597@2, exp. 12/14/2015; 1450@5, exp. 11/19/2015; 1748@2, exp. 1/4/2016; 1599@4, exp. 12/14/2015; 1447@3, exp. 11/19/2015; 1750@4, exp. 1/4/2016; 1601@5, exp. 12/14/2015; 1448@4, exp. 11/19/2015; 1740@2, exp. 1/3/2016; 1591@1, exp. 12/10/2015; 1436@2, exp. 11/18/2015; 1742@3, exp. 1/3/2016; 1594@3, exp. 12/10/2015; 1441@4, exp. 11/18/2015; 1739@1, exp. 1/3/2016; 1592@2, exp. 12/10/2015; 1443@5, exp. 11/18/2015; 1735@3, exp. 12/31/2015; 1583@3, exp. 12/9/2015; 1439@3, exp. 11/18/2015; 1731@1, exp. 12/31/2015; 1586@4, exp. 12/9/2015; 1435@1, exp. 11/18/2015; 1733@2, exp. 12/31/2015; 1580@1, exp. 12/9/2015; 1423@2, exp. 11/17/2015; 1737@4, exp. 12/31/2015; 1581@2, exp. 12/9/2015; 1433@7, exp. 11/17/2015; 1715@1, exp. 12/30/2015; 1588@5, exp. 12/9/2015; 1422@1, exp. 11/17/2015; 1718@3, exp. 12/30/2015; 1570@1, exp. 12/8/2015; 1417@3, exp. 11/16/2015; 1709@2, exp. 12/29/2015; 1571@2, exp. 12/8/2015; 1416@2, exp. 11/16/2015; 1707@1, exp. 12/29/2015; 1578@5, exp. 12/8/2015; 1420@4, exp. 11/16/2015; 1712@4, exp. 12/29/2015; 1576@4, exp. 12/8/2015; 1413@4, exp. 11/15/2015; 1710@3, exp. 12/29/2015; 1572@3, exp. 12/8/2015; 1412@3, exp. 11/15/2015; 1696@2, exp. 12/28/2015; 1562@1, exp. 12/7/2015; 1396@2, exp. 11/12/2015; 1698@3, exp. 12/28/2015; 1563@2, exp. 12/7/2015; 1402@5, exp. 11/12/2015; 1695@1, exp. 12/28/2015; 1564@3, exp. 12/7/2015; 1398@4, exp. 11/12/2015; 1699@4, exp. 12/28/2015; 1558@1, exp. 12/3/2015; 1392@7, exp. 11/11/2015; 1689@1, exp. 12/27/2015; 1554@4, exp. 12/2/2015; 1388@5, exp. 11/11/2015; 1692@3, exp. 12/27/2015; 1560@2, exp. 12/3/2015; 1385@4, exp. 11/11/2015; 1690@2, exp. 12/27/2015; 1556@5, exp. 12/2/2015; 1372@3, exp. 11/10/2015; 1683@1, exp. 12/24/2015; 1548@1, exp. 12/2/2015; 1371@2, exp. 11/10/2015; 1686@3, exp. 12/24/2015; 1550@3, exp. 12/2/2015; 1369@1, exp. 11/10/2015; 1684@2, exp. 12/24/2015; 1549@2, exp. 12/2/2015; 1360@2, exp. 11/9/2015; 1674@3, exp. 12/23/2015; 1536. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pine Pharmaceuticals, LLC
- Distributor
- Nationwide and Puerto Rico
- Lot
- Lot #: 1956@2, exp. 2/2/2016; 1954@1, exp. 2/2/2016; 1958@3, exp. 2/2/2016; 1943@2, exp. 2/1/2016; 1942@1, exp. 2/1/2016; 1944@3, exp. 2/1/2016; 1938@1, exp. 1/31/2016; 1939@2, exp. 1/31/2016; 1931@1, exp. 1/28/2016; 1932@2, exp. 1/28/2016; 1935@3, exp. 1/28/2016; 1925@1, exp. 1/27/2016; 1927@2, exp. 1/27/2016; 1928@3, exp. 1/27/2016; 1913@3, exp. 1/26/2016; 1917@4, exp. 1/26/2016; 1911@1, exp. 1/26/2016; 1921@6, exp. 1/26/2016; 1906@3, exp. 1/25/2016; 1903@1, exp. 1/25/2016; 1904@2, exp. 1/25/2016; 1899@3, exp. 1/24/2016; 1896@2, exp. 1/24/2016; 1895@1, exp. 1/24/2016; 1886@2, exp. 1/21/2016; 1893@5, exp. 1/21/2016; 1890@4, exp. 1/21/2016; 1885@1, exp. 1/21/2016; 1888@3, exp. 1/21/2016; 1879@5, exp. 1/20/2016; 1872@1, exp. 1/20/2016; 1875@3, exp. 1/20/2016; 1873@2, exp. 1/20/2016; 1867@5, exp. 1/19/2016; 1870@6, exp. 1/19/2016; 1866@4, exp. 1/19/2016; 1854@4, exp. 1/18/2016; 1853@5, exp. 1/18/2016; 1855@6, exp. 1/18/2016; 1839@3, exp. 1/17/2016; 1836@1, exp. 1/17/2016; 1831@2, exp. 1/14/2016; 1813@2, exp. 1/14/2016; 1830@1, exp. 1/14/2016; 1825@1, exp. 1/13/2016; 1818@4, exp. 1/13/2016; 1827@2, exp. 1/13/2016; 1816@3, exp. 1/12/2016; 1812@1, exp. 1/13/2016; 1804@4, exp. 12/31/2015; 1799@6, exp. 1/10/2016; 1797@5, exp. 1/10/2016; 1789@3, exp. 1/7/2016; 1635@5, exp. 12/17/2015; 1490@1, exp. 11/25/2015; 1790@4, exp. 1/7/2016; 1633@4, exp. 12/17/2015; 1492@2, exp. 11/25/2015; 1786@1, exp. 1/7/2016; 1628@2, exp. 12/17/2015; 1497@5, exp. 11/25/2015; 1788@2, exp. 1/7/2016; 1629@3, exp. 12/17/2015; 1486@7, exp. 11/24/2015; 1764@1, exp. 1/6/2016; 1617@1, exp. 12/16/2015; 1476@3, exp. 11/24/2015; 1768@3, exp. 1/6/2016; 1623@4, exp. 12/16/2015; 1474@1, exp. 11/24/2015; 1769@4, exp. 1/6/2016; 1620@3, exp. 12/16/2015; 1466@2, exp. 11/23/2015; 1757@2, exp. 1/5/2016; 1625@5, exp. 12/16/2015; 1473@5, exp. 11/23/2015; 1756@1, exp. 1/5/2016; 1618@2, exp. 12/16/2015; 1465@1, exp. 11/23/2015; 1762@4, exp. 1/5/2016; 1608@2, exp. 12/15/2015; 1460@2, exp. 11/22/2015; 1749@3, exp. 1/4/2016; 1610@3, exp. 12/15/2015; 1458@1, exp. 11/22/2015; 1746@1, exp. 1/4/2016; 1597@2, exp. 12/14/2015; 1450@5, exp. 11/19/2015; 1748@2, exp. 1/4/2016; 1599@4, exp. 12/14/2015; 1447@3, exp. 11/19/2015; 1750@4, exp. 1/4/2016; 1601@5, exp. 12/14/2015; 1448@4, exp. 11/19/2015; 1740@2, exp. 1/3/2016; 1591@1, exp. 12/10/2015; 1436@2, exp. 11/18/2015; 1742@3, exp. 1/3/2016; 1594@3, exp. 12/10/2015; 1441@4, exp. 11/18/2015; 1739@1, exp. 1/3/2016; 1592@2, exp. 12/10/2015; 1443@5, exp. 11/18/2015; 1735@3, exp. 12/31/2015; 1583@3, exp. 12/9/2015; 1439@3, exp. 11/18/2015; 1731@1, exp. 12/31/2015; 1586@4, exp. 12/9/2015; 1435@1, exp. 11/18/2015; 1733@2, exp. 12/31/2015; 1580@1, exp. 12/9/2015; 1423@2, exp. 11/17/2015; 1737@4, exp. 12/31/2015; 1581@2, exp. 12/9/2015; 1433@7, exp. 11/17/2015; 1715@1, exp. 12/30/2015; 1588@5, exp. 12/9/2015; 1422@1, exp. 11/17/2015; 1718@3, exp. 12/30/2015; 1570@1, exp. 12/8/2015; 1417@3, exp. 11/16/2015; 1709@2, exp. 12/29/2015; 1571@2, exp. 12/8/2015; 1416@2, exp. 11/16/2015; 1707@1, exp. 12/29/2015; 1578@5, exp. 12/8/2015; 1420@4, exp. 11/16/2015; 1712@4, exp. 12/29/2015; 1576@4, exp. 12/8/2015; 1413@4, exp. 11/15/2015; 1710@3, exp. 12/29/2015; 1572@3, exp. 12/8/2015; 1412@3, exp. 11/15/2015; 1696@2, exp. 12/28/2015; 1562@1, exp. 12/7/2015; 1396@2, exp. 11/12/2015; 1698@3, exp. 12/28/2015; 1563@2, exp. 12/7/2015; 1402@5, exp. 11/12/2015; 1695@1, exp. 12/28/2015; 1564@3, exp. 12/7/2015; 1398@4, exp. 11/12/2015; 1699@4, exp. 12/28/2015; 1558@1, exp. 12/3/2015; 1392@7, exp. 11/11/2015; 1689@1, exp. 12/27/2015; 1554@4, exp. 12/2/2015; 1388@5, exp. 11/11/2015; 1692@3, exp. 12/27/2015; 1560@2, exp. 12/3/2015; 1385@4, exp. 11/11/2015; 1690@2, exp. 12/27/2015; 1556@5, exp. 12/2/2015; 1372@3, exp. 11/10/2015; 1683@1, exp. 12/24/2015; 1548@1, exp. 12/2/2015; 1371@2, exp. 11/10/2015; 1686@3, exp. 12/24/2015; 1550@3, exp. 12/2/2015; 1369@1, exp. 11/10/2015; 1684@2, exp. 12/24/2015; 1549@2, exp. 12/2/2015; 1360@2, exp. 11/9/2015; 1674@3, exp. 12/23/2015; 1536
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe, Rx only, Compounded by: Pine Pharmaceuticals 355 RiverwalkOctober 25, 2023
- FDAMoxifloxacin in Balanced Salt Solution 400 mcg/0.4 mL (100 mcg/0.1 mL) 1 mL syringes, Rx only, Compounded by:October 25, 2023
- FDACalcium chloride Solution for Intravenous Injection, 20 mg/mL, 500 mL bags, Rx only, Compounded by PineOctober 25, 2023
- FDALidocaine-phenylephrine 1%-1.5% 1mL Single Dose Vial, Rx only, Compounded by Pine Pharmaceuticals 355October 25, 2023
- FDAEnergique, Homeopathic Remedy, Headache Pain & Sinus Pressure Relief, Topical Spray, 1 fl oz (30 ml) bottles,January 27, 2016
- FDABevacizumab 1.25 mg/0.05 mL filled to 0.06 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- PineJanuary 27, 2016
Questions about this recall
Was Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150. recalled?
Yes. FDA published recall D-0581-2016 on January 27, 2016. Reported hazard: Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
What should I do if I have this product?
Voluntary: Firm initiated · Letter